Understanding Benzodiazepine and Non-benzodiazepine Sedative Use

McGill University

Status: Unknown

Conditions: Deprescription; Frailty; Aged

Treatments: Behavioral: EMPOWER Educational Brochure

Study type: Interventional

Funder types: Other

Identifiers

NCT02833272

15-372

Details and patient eligibility

About

Inappropriate medication use among the elderly ranges from 11% to 62% and is a major concern for patient safety. Benzodiazepines account for approximately 20 to 25% of inappropriate medications prescribed to the elderly, thus reducing their inappropriate use could have a substantial impact on patient safety and overall well-being among elderly patients. The Choosing Wisely Canada- Geriatrics guidelines for high value health care recommend against the prescription of benzodiazepines or other sedative-hypnotics (Z drugs) in older adults as first choice for insomnia, agitation or delirium. Despite evidence of potential harms, benzodiazepines and non-benzodiazepine sedatives (including the "Z-drugs": eszopiclone, zopiclone, zolpidem and zaleplon, henceforth referred to as "sedatives") continue to be prescribed inappropriately to patients in hospital and community settings.

Our primary objective is to facilitate the deprescription of benzodiazepine and non-benzodiazepine sedative hypnotics (sedatives) using a combination of physician education sessions and an updated patient educational pamphlet based on Tannenbaum's EMPOWER study conducted in a community-based setting.

Full description

This study will be a pragmatic before-after intervention trial at the McGill University Health Centre (MUHC) Royal Victoria Hospital (Glen Site) using historical controls from 2014-2016 at our hospital.The intervention will begin July 2016 and conclude January 2016.

The intervention will include the following components:

1. Educational campaign toward physicians about benzodiazepine and Z-drug prescriptions:

   An educational campaign about the purpose of the study and risks of benzodiazepine and sedative prescriptions will be delivered to physicians in each intervention cluster. The educational campaign will include a presentation by the chief of the medical service at teaching rounds at the beginning of the intervention, an electronic message sent to all physicians on the medical service, and posting of the Choosing Wisely Canada- Geriatrics guidelines.

2. In-hospital patient education campaign:

Patients will be identified from the pharmacy database and validated by a research associate in collaboration with the unit pharmacists based on the patient's best possible medication history taken at time of admission. Eligibility will be confirmed by the patient's treating physician with support from the principal investigator and site coordinators. Patients will receive a previously validated (in the outpatient setting) educational brochure about the risks of chronic sedative use and how to stop using them through a tapering regimen. The booklet currently includes information about benzodiazepines but will be adapted to also include information about sedatives. The preparation of the brochure has been validated in both English and French for comprehension and readability.

Clusters will be defined by clinical teaching unit (CTU) at the Royal Victoria Hospital, - the C9 CTU and D9 CTU. Follow up of discharged patients will be until 30 and 90 days post-discharge.

Enrollment: 50 estimated patients

Sex: All

Ages: 65 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients 65 years or older admitted to study units
• Have a benzodiazepine or sedative prescription used at least 3 times in the week prior to enrolment

Exclusion criteria

• Less than 65 years of age
• Admitted for the treatment of alcohol or benzodiazepine withdrawal
• Not having a prescription for benzodiazepines or Z-drugs
• Not reporting use of either medication at least 3 times in the week prior to admission
• Not being enrolled in the provincial drug plan
• Opting out of the provincial drug database (DSQ)
• Previous enrolment in the study
• Patients expected to die before primary endpoint can be realized (e.g., patients admitted for end of life care or prognosis of 3 months or less)
• Patient lives in nursing home and has dementia without an identifiable proxy
• Inability for patient or proxy to speak English or French
• No means of contacting patient or proxy after discharge

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

EMPOWER Educational Brochure

Experimental group

Description:

This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.

Treatment:

Behavioral: EMPOWER Educational Brochure